IDEAYA Biosciences, Inc. (IDYA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.94: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 4.82; Below-average business quality.
IDEAYA Biosciences is a precision medicine oncology company with nine clinical-stage product candidates across four focus areas including darovasertib for uveal melanoma (Phase 2/3 registration-enabling trial), plus ADC/DDR combinations, MTAP pathway, and next-generation... Read more
Sell if holding. Engine safety override at $28.94: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 4.82; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.94: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 4.82; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $27.13. Score 5.7/10, moderate confidence.
Take-profit target: $47.53 (+64.2% upside). Prior stop was $27.13. Stop-loss: $27.13.
Quality below floor (1.9 < 4.0).
IDEAYA Biosciences, Inc. trades at a P/E of N/A (forward -8.4). TrendMatrix value score: 6.4/10. Verdict: Sell.
25 analysts cover IDYA with a consensus score of 4.2/5. Average price target: $53.
What does IDEAYA Biosciences, Inc. do?IDEAYA Biosciences is a precision medicine oncology company with nine clinical-stage product candidates across four...
IDEAYA Biosciences is a precision medicine oncology company with nine clinical-stage product candidates across four focus areas including darovasertib for uveal melanoma (Phase 2/3 registration-enabling trial), plus ADC/DDR combinations, MTAP pathway, and next-generation therapies. The company has no approved products or revenue and reported a net loss in 2025.